$6.83
+0.15
(+2.25%)▲
Insights on Avid Bioservices Inc
Revenue is down for the last 3 quarters, 39.79M → 25.39M (in $), with an average decrease of 19.0% per quarter
Netprofit is down for the last 4 quarters, 461.0K → -9.50M (in $), with an average decrease of 366.2% per quarter
In the last 1 year, Novo Nordisk A/s has given 52.6% return, outperforming this stock by 116.6%
In the last 3 years, Novo Nordisk A/s has given 247.4% return, outperforming this stock by 315.9%
2.64%
Downside
Day's Volatility :3.34%
Upside
0.73%
40.41%
Downside
52 Weeks Volatility :78.79%
Upside
64.41%
Period | Avid Bioservices Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -1.3% | 2.0% | 0.0% |
6 Months | 3.02% | 11.7% | 0.0% |
1 Year | -63.22% | 5.8% | 1.3% |
3 Years | -67.49% | 14.2% | -22.1% |
Market Capitalization | 405.4M |
Book Value | $2.91 |
Earnings Per Share (EPS) | -0.18 |
Wall Street Target Price | 12.25 |
Profit Margin | -8.12% |
Operating Margin TTM | -44.19% |
Return On Assets TTM | -1.36% |
Return On Equity TTM | -6.28% |
Revenue TTM | 140.9M |
Revenue Per Share TTM | 2.25 |
Quarterly Revenue Growth YOY | -26.900000000000002% |
Gross Profit TTM | 31.5M |
EBITDA | -501.0K |
Diluted Eps TTM | -0.18 |
Quarterly Earnings Growth YOY | -0.8 |
EPS Estimate Current Year | -0.27 |
EPS Estimate Next Year | -0.06 |
EPS Estimate Current Quarter | -0.06 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 79.36%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 53.6M | ↓ 6.96% |
Net Income | -21.8M | ↓ 22.54% |
Net Profit Margin | -40.68% | ↑ 8.18% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 53.6M | ↓ 0.03% |
Net Income | -4.2M | ↓ 80.68% |
Net Profit Margin | -7.86% | ↑ 32.82% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 59.7M | ↑ 11.38% |
Net Income | -7.3M | ↑ 72.15% |
Net Profit Margin | -12.15% | ↓ 4.29% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 95.9M | ↑ 60.58% |
Net Income | 11.2M | ↓ 254.52% |
Net Profit Margin | 11.7% | ↑ 23.85% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 119.6M | ↑ 24.75% |
Net Income | 127.7M | ↑ 1038.71% |
Net Profit Margin | 106.75% | ↑ 95.05% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 149.3M | ↑ 24.81% |
Net Income | 560.0K | ↓ 99.56% |
Net Profit Margin | 0.38% | ↓ 106.37% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 36.7M | ↑ 17.5% |
Net Income | 1.6M | ↓ 98.65% |
Net Profit Margin | 4.26% | ↓ 365.94% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 34.8M | ↓ 5.27% |
Net Income | -1.2M | ↓ 173.91% |
Net Profit Margin | -3.33% | ↓ 7.59% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 38.0M | ↑ 9.38% |
Net Income | 461.0K | ↓ 139.88% |
Net Profit Margin | 1.21% | ↑ 4.54% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 39.8M | ↑ 4.68% |
Net Income | -309.0K | ↓ 167.03% |
Net Profit Margin | -0.78% | ↓ 1.99% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 37.7M | ↓ 5.21% |
Net Income | -2.1M | ↑ 577.35% |
Net Profit Margin | -5.55% | ↓ 4.77% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 25.4M | ↓ 32.69% |
Net Income | -9.5M | ↑ 354.32% |
Net Profit Margin | -37.44% | ↓ 31.89% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 95.8M | ↓ 18.92% |
Total Liabilities | 40.0M | ↓ 37.98% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 78.4M | ↓ 18.13% |
Total Liabilities | 25.3M | ↓ 36.72% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 107.6M | ↑ 37.28% |
Total Liabilities | 65.7M | ↑ 159.5% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 265.5M | ↑ 146.71% |
Total Liabilities | 187.8M | ↑ 185.7% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 429.8M | ↑ 61.89% |
Total Liabilities | 255.3M | ↑ 35.97% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 451.1M | ↑ 4.93% |
Total Liabilities | 261.6M | ↑ 2.45% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 451.2M | ↑ 4.97% |
Total Liabilities | 272.2M | ↑ 6.62% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 441.9M | ↓ 2.08% |
Total Liabilities | 260.7M | ↓ 4.25% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 450.4M | ↑ 1.94% |
Total Liabilities | 265.0M | ↑ 1.68% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 451.1M | ↑ 0.14% |
Total Liabilities | 261.6M | ↓ 1.3% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 442.3M | ↓ 1.93% |
Total Liabilities | 251.7M | ↓ 3.76% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 454.6M | ↑ 2.78% |
Total Liabilities | 271.0M | ↑ 7.64% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -26.8M | ↓ 32.73% |
Investing Cash Flow | -19.0K | ↓ 99.36% |
Financing Cash Flow | 22.3M | ↓ 21.0% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -11.6M | ↓ 56.68% |
Investing Cash Flow | 4.5M | ↓ 24015.79% |
Financing Cash Flow | -2.9M | ↓ 112.87% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 5.8M | ↓ 150.25% |
Investing Cash Flow | -3.8M | ↓ 183.89% |
Financing Cash Flow | 1.1M | ↓ 138.28% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 31.2M | ↑ 435.13% |
Investing Cash Flow | -9.9M | ↑ 158.76% |
Financing Cash Flow | 112.3M | ↑ 10149.54% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 9.5M | ↓ 69.65% |
Investing Cash Flow | -56.4M | ↑ 471.89% |
Financing Cash Flow | 3.2M | ↓ 97.15% |
FY23 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -12.9M | ↓ 236.15% |
Investing Cash Flow | -77.6M | ↑ 37.63% |
Financing Cash Flow | 2.9M | ↓ 9.26% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -5.0M | ↓ 922.55% |
Investing Cash Flow | -6.9M | ↓ 71.81% |
Financing Cash Flow | 929.0K | ↑ 469.94% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -3.7M | ↓ 25.76% |
Investing Cash Flow | -34.5M | ↑ 398.38% |
Financing Cash Flow | 400.0K | ↓ 56.94% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -6.9M | ↑ 85.04% |
Investing Cash Flow | -11.3M | ↓ 67.17% |
Financing Cash Flow | 868.0K | ↑ 117.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 2.8M | ↓ 140.48% |
Investing Cash Flow | -24.9M | ↑ 119.59% |
Financing Cash Flow | 704.0K | ↓ 18.89% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -278.0K | ↓ 109.93% |
Investing Cash Flow | -14.1M | ↓ 43.26% |
Financing Cash Flow | 748.0K | ↑ 6.25% |
Sell
Neutral
Buy
Avid Bioservices Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Avid Bioservices Inc | 0.0% | 3.02% | -63.22% | -67.49% | 49.45% |
Moderna, Inc. | -2.26% | 35.27% | -21.9% | -39.25% | 318.83% |
Regeneron Pharmaceuticals, Inc. | -5.59% | 12.81% | 13.84% | 81.04% | 166.5% |
Novo Nordisk A/s | -0.32% | 31.91% | 50.92% | 247.21% | 431.9% |
Vertex Pharmaceuticals Incorporated | -2.67% | 11.53% | 21.99% | 86.62% | 131.89% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Avid Bioservices Inc | 1250.0 | NA | NA | -0.27 | -0.06 | -0.01 | NA | 2.91 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.9 | 25.9 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.09 | 47.09 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.76 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Avid Bioservices Inc | Buy | $405.4M | 49.45% | 1250.0 | -8.12% |
Moderna, Inc. | Buy | $40.0B | 318.83% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.8B | 166.5% | 25.9 | 30.14% |
Novo Nordisk A/s | Buy | $558.9B | 431.9% | 47.09 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.4B | 131.89% | 28.81 | 36.68% |
BlackRock Inc
State Street Corporation
T. Rowe Price Investment Management,Inc.
Millennium Management LLC
Vanguard Group Inc
AltraVue Capital, LLC
avid bioservices, a subsidiary of peregrine pharmaceuticals, inc. (nasdaq: pphm), is a unique contract manufacturing organization ("cmo") partner dedicated to the development and production of monoclonal antibodies, recombinant proteins and enzymes produced in mammalian cell culture. our extensive experience at all stages of development enables us to provide comprehensive development, manufacturing and support services to navigate a biologic from concept to commercialization.
Organization | Avid Bioservices Inc |
Employees | 365 |
CEO | Mr. Nicholas Stewart Green B.Sc., MBA |
Industry | Health Technology |